載入...
Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER(+)HER2(−)Rb wild-type and knock-down in breast cancer cell lines
BACKGROUND: Breast cancer (BC) is the second most common type of cancer worldwide. Among targeted therapies for Hormone Receptor-positive (HR(+)) and Human Epidermal growth factor Receptor 2-negative (HER2(−)) BC, the Cyclin-Dependent Kinases (CDK4/6) are targeted by inhibitors such as Ribociclib (R...
Na minha lista:
| 發表在: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7678099/ https://ncbi.nlm.nih.gov/pubmed/33213401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07619-1 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|